๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

A Study of Fruquintinib in Adults With Metastatic Colorectal Cancer in Poland

Recruitingn/aAges 18 Years - anyAllTakeda
NCT07623174 on ClinicalTrials.gov โ†—
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Metastatic colorectal cancer or mCRC is a cancer that starts in the parts of the large intestine (the colon or rectum) and has already spread to other parts of the body. This cancer can be hard to treat because it can behave differently from one person to another. Over time, treatments may stop working, and side effects can build up. In later treatment stages, there are only a few standard medicine options available. Because of this, studies often look at both how long people live and how treatment affects quality of life. The main aim of this study is to see how long adults in Poland with mCRC live without their cancer getting worse (progression-free survival or PFS) when they receive fruquintinib after at least two previous treatments. Fruquintinib (TAK 113) is a medicine taken by mouth that is designed to slow tumor growth. Other aim is to find out how long adults in Poland with mCR

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: 1. Adult participants (aged 18 years and older) with mCRC who are eligible for treatment with fruquintinib under the national drug program B.4 and will receive fruquintinib as third or subsequent line treatment after progression on or intolerance to trifluride/tipiracil. 2. Participants who signed informed consent to participate in the study at the time of enrollment and prior to the fruquintinib treatment initiation. 3. Participants for whom adequate medical records are available to support the data collection requirements. Exclusion Criteria: 1\. Participant currently participates or plans to participate in an interventional clinical trial.
๐Ÿ’Š

What it tests

  • No intervention
๐Ÿ“

Where

10 sites
Wielkopolskie Centrum Onkologii im. Marii Sklodowskiej Curie, Oddzial Onkologii Klinicznej i Immunoonkologii z Pododdzialem Dziennym i Izb Przyjec
Poznan, Poland
Centrum Onkologii im. prof. Franciszka Lukaszczyka w Bydgoszczy, Ambulatorium Chemoterapii
Bydgoszcz, Poland
Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie, Oddzial Kliniczny Onkologii
Krakow, Poland
Uniwersytecki Szpital Kliniczny Nr 1 w Lublinie, Klinika Chorob Metabolicznych i Immunoonkologii, Oddzial Onkologii Klinicznej
Lublin, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Klinika Onkologii i Radioterapii
Warsaw, Poland
Samodzielny Publiczny Zaklad Opieki Zdrowotnej Opolskie Centrum Onkologii im. Prof. Tadeusza Koszarowskiego w Opolu, Klinika Onkologii, Odcinek Dzienny
Opole, Poland
Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu, Oddzial Onkologiczny z Pod. Dziennej Chemioterapii
Przemyล›l, Poland
Bialostockie Centrum Onkologii im. M. Sklodowskiej-Curie w Bialymstoku, Oddzial Onkologii Klinicznej im. dr E. Pileckiej z pododdzialem Chemioterapii Dziennej
Bialystok, Poland

โ€ฆand 2 more on ClinicalTrials.gov.

๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy